On July 31, 2020, Shibutani, Masatsune; Nagahara, Hisashi; Fukuoka, Tatsunari; Iseki, Yasuhito; Wang, En; Okazaki, Yuki; Kashiwagi, Shinichiro; Maeda, Kiyoshi; Hirakawa, Kosei; Ohira, Masaichi published an article.Computed Properties of 65-71-4 The title of the article was Combining bevacizumab with trifluridine/thymidine phosphorylase inhibitor improves the survival outcomes regardless of the usage history of bevacizumab in front-line treatment of patients with metastatic colorectal cancer. And the article contained the following:
The efficacy of trifluridine/thymidine phosphorylase inhibitor (FTD/TPI) plus bevacizumab as later-line treatment for metastatic colorectal cancer (mCRC) has been demonstrated. However, little is known about the impact of a usage history of bevacizumab in front-line treatment on the clin. benefit of combining bevacizumab with FTD/TPI. A total of 62 patients with mCRC treated with FTD/TPI±bevacizumab was enrolled and assessed for chemotherapeutic efficacy and adverse events. Regardless of the usage history of bevacizumab in front-line treatment, the FTD/TPI plus bevacizumab group had a significantly better progression-free survival rate than the FTD/TPI monotherapy group, and no significant differences in the safety profile were observed between the two groups. Combining bevacizumab with FTD/TPI improves the survival outcomes with manageable toxicity, regardless of the usage history of bevacizumab in front-line treatment, in patients with mCRC. The experimental process involved the reaction of 5-Methylpyrimidine-2,4(1H,3H)-dione(cas: 65-71-4).Computed Properties of 65-71-4
The Article related to metastatic colorectal cancer bevacizumab trifluridine thymidine phosphorylase inhibitor survival, ftd/tpi, tas-102, bevacizumab, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Computed Properties of 65-71-4
Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia